. 2009 Jan 26;11(3):385–392. doi: 10.1038/aja.2008.34

Table 3. Effects on safety indicators (mean ± SD).

Group	Baseline	3 weeks	6 weeks
Physical safety indicators
Weight (kg)
Placebo	70.38 ± 9.27	70.59 ± 9.51	70.59 ± 9.37
D-004	71.03 ± 10.30	69.16 ± 8.14	68.63 ± 8.28
Pulse rate (beats min⁻¹)
Placebo	72.94 ± 4.48	72.53 ± 4.90	73.88 ± 3.71
D-004	73.18 ± 5.20	70.75 ± 5.65	73.60 ± 4.08
Diastolic arterial pressure (mmHg)
Placebo	71.18 ± 7.81	68.23 ± 8.83	71.18 ± 7.81
D-004	73.53 ± 6.79	71.87 ± 5.44	72.00 ± 5.61
Systolic arterial pressure (mmHg)
Placebo	112.35 ± 9.70	112.06 ± 9.53	111.18 ± 8.57
D-004	117.06 ± 10.47	115.00 ± 6.01	114.67 ± 6.40
Blood indicators
PSA (ng mL⁻¹)
Placebo	0.94 ± 0.69		1.06 ± 0.79
D-004	1.06 ± 0.79		0.99 ± 0.66
Total cholesterol (mmol L⁻¹)
Placebo	4.30 ± 0.59		4.38 ± 0.60
D-004	4.39 ± 0.74		4.49 ± 0.52
Triglycerides (mmol L⁻¹)
Placebo	1.09 ± 0.44		0.99 ± 0.52
D-004	1.28 ± 0.47		1.20 ± 0.52
ALT (U L⁻¹)
Placebo	19.47 ± 9.75		21.12 ± 7.93
D-004	18.76 ± 7.96		17.87 ± 3.78
CPK (U L⁻¹)
Placebo	158.59 ± 79.12		174.94 ± 74.94
D-004	158.18 ± 48.89		167.50 ± 55.09
Glucose (mmol L⁻¹)
Placebo	4.56 ± 0.52		4.45 ± 0.49
D-004	4.51 ± 0.56		4.29 ± 0.56
Creatinine (μmol L⁻¹)
Placebo	84.41 ± 8.52		87.35 ± 9.69
D-004	88.00 ± 10.11		88.00 ± 8.66
Haemoglobin (g 100 mL^-1)
Placebo	14.24 ± 0.82		14.28 ± 1.01
D-004	14.43 ± 0.74		14.61 ± 0.84
Haematocrit (%)
Placebo	43.03 ± 2.29		43.30 ± 2.03
D-004	43.15 ± 2.30		44.21 ± 2.11
Red blood cells (× 10³)
Placebo	4.83 ± 0.36		4.79 ± 0.31
D-004	4.72 ± 0.33		4.75 ± 0.36
White blood cells (× 10³)
Placebo	5.83 ± 1.28		5.66 ± 1.31
D-004	5.69 ± 1.27		5.77 ± 1.20

Abbreviations: ALT, alanine amino transferase; CPK, creatine phosphokinase; PSA, prostate-specific antigen.